News / Government & Legislative Affairs / Small Business
AdvaMed Statement on House Passage of Critical R&D Tax Provision
January 31, 2024
AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker upon the passage of a research and development expensing tax provision critical to medtech innovation in the House of Representatives.
News / Business Development / Government & Legislative Affairs
AdvaMed Urges Congress to Pass R&D Tax Provision Promoting, Preserving Medtech Innovation
January 24, 2024
Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today urged Congress to enact a research and development expensing tax provision critical to medtech innovation. The provision would delay a change requiring businesses to deduct their research and development expenses over five years, allowing immediate deduction.
Resource / Business Development
Disruptive Business Model Innovation in MedTech
December 1, 2023
Learn how to develop and maintain an effective and innovative business model to stand out and find success in the medtech industry.
Event / China / Global & Trade / Small Business
China Medical Device Webinar with AdvaMed Accel for U.S. Exporters
October 18, 2023
Join us for a breakdown of the Chinese medical device market, to review the current regulatory requirements and pathways, and address I.P. protection in China for U.S. companies.
Event / Investor Relations / Small Business
What Now?: Navigating the Banking System in the Aftermath of Recent Collapses
May 18, 2023
3:00 PM – 4:00 PM
News / Small Business
AdvaMed Calls on Congress to Reform Tax Code to Support Small Businesses
April 26, 2023
Following the introduction of the bipartisan American Innovation and Jobs Act in the U.S. Senate and its House companion the American Innovation and R&D Competitiveness Act, AdvaMed, the MedTech Association, called on lawmakers to quickly pass the legislation which would allow for small companies to deduct their research and development expenses in the year they are incurred. Currently, companies are required to deduct their expenses over the course of five years.
Blog / Coverage & Payment / Diagnostics / Global & Trade / Government & Legislative Affairs / Health Equity / Legal / Regulatory Affairs / Small Business
AdvaMed’s Medical Innovation Agenda for the 118th Congress
February 28, 2023
AdvaMed’s medtech priorities for the 118th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
Blog / Coverage & Payment / Global & Trade / Government & Legislative Affairs / Health Equity / Investor Relations / Regulatory Affairs / Small Business
AdvaMed’s Top 10 Medtech Wins in 2022
December 22, 2022
From MDUFA V and the major investments in semiconductor chip manufacturing in the CHIPS Act, to addressing global supply chain issues and supporting our AdvaMed Accel companies, 2022 was a year like no other.